Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

merck sharp & dohme llc - varicella-zoster virus strain oka/merck live antigen (unii: gpv39zgd8c) (varicella-zoster virus strain oka/merck live antigen - unii:gpv39zgd8c) - varicella-zoster virus strain oka/merck live antigen 1350 [pfu] in 0.5 ml - varivax is a vaccine indicated for active immunization for the prevention of varicella in individuals 12 months of age and older. do not administer varivax to individuals with a history of anaphylactic or severe allergic reaction to any component of the vaccine (including neomycin and gelatin) or to a previous dose of a varicella-containing vaccine. do not administer varivax to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. disseminated varicella disease and extensive vaccine-associated rash have been reported in individuals who are immunosuppressed or immunodeficient who were inadvertently vaccinated with a varicella-containing vaccine. do not administer varivax to individuals with an active febrile illness with fever >101.3°f (>38.5°c). do not administer varivax to individuals with active, untreated tuberculosis (tb). do not administer varivax to individuals who are pregnant or planning on becoming pregnant in the next 3 months. wild-type varicella is known to cau

Канада - Енглески - Health Canada

merck frosst canada & cie, merck frosst canada & co. - varicella-zoster virus vaccine live attenuated (oka/merck strain) - powder for solution - 1350unit - varicella-zoster virus vaccine live attenuated (oka/merck strain) 1350unit - vaccines

Канада - Енглески - Health Canada

merck frosst canada & cie, merck frosst canada & co. - varicella-zoster virus vaccine live attenuated (oka/merck strain) - powder for solution - 1350unit - varicella-zoster virus vaccine live attenuated (oka/merck strain) 1350unit - vaccines

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - fosaprepitant dimeglumine 197.5mg ((free acid) (120.8 mg)) - powder for injection - 115 mg - active: fosaprepitant dimeglumine 197.5mg ((free acid) (120.8 mg)) excipient: disodium edetate hydrochloric acid lactose polysorbate 80 sodium hydroxide water for injection

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - fosaprepitant dimeglumine 257.6mg ((free acid) (157.5 mg)) - powder for injection - 150 mg - active: fosaprepitant dimeglumine 257.6mg ((free acid) (157.5 mg)) excipient: disodium edetate hydrochloric acid lactose polysorbate 80 sodium hydroxide water for injection - indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: · highly emetogenic cancer chemotherapy · moderately emetogenic cancer chemotherapy in combination with other antiemetic agents.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 30 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 60 microgram; hpv type 18 l1 protein, quantity: 40 microgram; hpv type 31 l1 protein, quantity: 20 microgram; hpv type 33 l1 protein, quantity: 20 microgram; hpv type 45 l1 protein, quantity: 20 microgram; hpv type 52 l1 protein, quantity: 20 microgram; hpv type 58 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: polysorbate 80; aluminium; histidine; sodium chloride; borax; water for injections - gardasil 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,gardasil 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). immunogenicity studies of gardasil 9 have been conducted relating to females over 26 years of age (see section 5.1 clinical trials for gardasil 9).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 30 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 60 microgram; hpv type 18 l1 protein, quantity: 40 microgram; hpv type 31 l1 protein, quantity: 20 microgram; hpv type 33 l1 protein, quantity: 20 microgram; hpv type 45 l1 protein, quantity: 20 microgram; hpv type 52 l1 protein, quantity: 20 microgram; hpv type 58 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: sodium chloride; histidine; borax; aluminium; water for injections; polysorbate 80 - gardasil 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,gardasil 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). immunogenicity studies of gardasil 9 have been conducted relating to females over 26 years of age (see section 5.1 clinical trials for gardasil 9).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - alendronate sodium,calcium carbonate,colecalciferol -

Сингапур - Енглески - HSA (Health Sciences Authority)

merck pte. ltd. - choriogonadotropin alfa - injection, solution - 250 mcg - choriogonadotropin alfa 250 mcg

Јужноафричка Република - Енглески - South African Health Products Regulatory Authority (SAHPRA)

merck generics rsa (pty) ltd - capsules - see ingredients - each capsule contains piroxicam 10,0 mg